

# **A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia**

Last Update: Jun 22, 2025

A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment

ClinicalTrials.gov Identifier:

[NCT05648968](#)

Novartis Reference Number: CVAY736O12301

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

## **Study Description**

The purpose of this study is to evaluate efficacy and safety of Ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment. The primary objective is to demonstrate that either dose of Ianalumab induces a durable hemoglobin response compared to placebo in patients with wAIHA.

The key secondary objective is to demonstrate that either dose of Ianalumab maintains a durable hemoglobin response that is sustained beyond end of the treatment period, compared to placebo.

Participants are randomized to two different doses of Ianalumab or placebo. Participants who were assigned to placebo arm and not responding to treatment may be treated with open label Ianalumab using the higher dose.

The investigational treatment will be supplied in a double-blinded manner. For the open label period, Ianalumab will be provided in an open label manner.

In addition to the randomized treatment (Ianalumab or placebo), specific supportive care medication as defined in the protocol is allowed. If clinically indicated (e.g., to ensure patient safety), the treating physician may also administer rescue medication.

The study consists of the treatment period, efficacy and safety follow-up periods. The visit frequency will be every other week during the treatment and primary endpoint follow up period; for safety monitoring monthly during the first 20 weeks after last dose and afterwards quarterly up to 2 years from the last dose. For participants in durable response, additional visits for efficacy will occur monthly during the first 2 years after the last dose, and afterwards quarterly until loss of response or end of study, latest until up to 39 months post randomization of the last participant.

Condition

Warm Autoimmune Hemolytic Anemia (wAIHA)

Phase  
Phase3  
Overall Status  
Recruiting  
Number of Participants  
90  
Start Date  
Dec 30, 2022  
Completion Date  
May 02, 2029  
Gender  
All  
Age(s)  
18 Years - 100 Years (Adult, Older Adult)

## Interventions

Biological

### Ianalumab

i.v. infusion, prepared from concentrate solution  
Drug

### Placebo

i.v. infusion, prepared from matching placebo

## Eligibility Criteria

Key Inclusion Criteria:

- \* 18 years and older at time of signing consent
- \* Patients with primary or secondary wAIHA documented by positive direct antiglobulin test specific for anti-IgG or anti-IgA, who had an insufficient response to, or relapsed after at least one line of treatment, including patients with steroid resistance, dependence or intolerance
- \* Hemoglobin concentration at screening and at Week 1  $\geq 5$  g/dL and  $< 10$  g/dL, associated with presence of symptoms related to anemia
- \* The dose of supportive care must be stable for at least 4 weeks prior to randomization into the study

Key Exclusion Criteria:

- \* wAIHA secondary to hematologic disease involving bone marrow (e.g., CLL) or another immunologic disease requiring prohibited medication as per protocol. Patients with autoimmune diseases after wash-out from the treatments are allowed.
- \* Presence of other forms of AIHA (cold or intermediate forms), Evans Syndrome or other cytopenias
- \* Prior use of B-cell depleting therapy (e.g., rituximab) within 12 weeks prior to randomization, or without hematological response to the last course of B-cell depleting therapy
- \* Neutrophils:  $< 1000/\text{mm}^3$

- \* Serum creatinine  $\geq 1.5 \times$  upper limit of normal (ULN)
- \* Immunoglobulin G (IgG)  $\leq 5\text{g/L}$
- \* Active viral, bacterial or other infections (including tuberculosis and SARS-CoV-2) requiring systemic treatment at time of screening, or history of recurrent clinically significant infection
- \* Positivity for hepatitis C virus, hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb). HBcAb positive patients can be enrolled if HBsAg negative, HBV DNA negative, no pre-existing liver fibrosis is present and antiviral prophylaxis is given.
- \* Known history of primary or secondary immunodeficiency, or a positive human immune deficiency virus (HIV) test result
- \* Live or live-attenuated vaccination within 4 weeks before randomization
- \* History of splenectomy

Other protocol-defined Inclusion/Exclusion may apply.

## **Argentina**

### **Novartis Investigative Site**

Recruiting

Caba,Buenos Aires,C1414drk,Argentina

### **Novartis Investigative Site**

Recruiting

Ciudad Autonoma de Bs As,Buenos Aires,C1015abo,Argentina

### **Novartis Investigative Site**

Recruiting

Buenos aires,C1039aac,Argentina

## **Australia**

### **Novartis Investigative Site**

Recruiting

Fitzroy,Victoria,3065,Australia

### **Novartis Investigative Site**

Recruiting

Canberra,Australian Capital Territory,2605,Australia

### **Novartis Investigative Site**

Recruiting

Melbourne,Victoria,3004,Australia

## **China**

### **Novartis Investigative Site**

Recruiting

Wuhan,Hubei,430022,China

### **Novartis Investigative Site**

Recruiting

Suzhou,Jiangsu,215004,China

### **Novartis Investigative Site**

Recruiting

Kunming,Yunnan,650101,China

### **Novartis Investigative Site**

Recruiting

Hangzhou,Zhejiang,310003,China

### **Novartis Investigative Site**

Recruiting

Dalian,116000,China

### **Novartis Investigative Site**

Recruiting

Tianjin,300020,China

### **Novartis Investigative Site**

Recruiting

Guangzhou,Guangdong,510515,China

### **Novartis Investigative Site**

Recruiting

Tianjin,300052,China

## **France**

### **Novartis Investigative Site**

Recruiting

Toulouse,31059,France

**Novartis Investigative Site**

Recruiting

Blois Cedex,41000,France

**Novartis Investigative Site**

Recruiting

Vandoeuvre Les Nancy,54511,France

**Novartis Investigative Site**

Recruiting

Caen,14033,France

**Novartis Investigative Site**

Recruiting

Nantes,44093,France

**Novartis Investigative Site**

Recruiting

Creteil,94010,France

**Novartis Investigative Site**

Recruiting

Le Mans,72000,France

**Novartis Investigative Site**

Recruiting

Lille,59037,France

**Novartis Investigative Site**

Recruiting

Nice,06202,France

**Germany**

**Novartis Investigative Site**

**Novartis Investigative Site**

Recruiting

Frankfurt am Main,Hessen,60590,Germany

**Novartis Investigative Site**

Recruiting

Dresden,01307,Germany

**Novartis Investigative Site**

Recruiting

Essen,45147,Germany

**Novartis Investigative Site**

Recruiting

Giessen,35392,Germany

**Novartis Investigative Site**

Recruiting

Hannover,30161,Germany

**Israel**

**Novartis Investigative Site**

Recruiting

Afula,1834111,Israel

**Novartis Investigative Site**

Recruiting

Petach Tikva,4941492,Israel

**Novartis Investigative Site**

Recruiting

Zerifin,7030000,Israel

**Novartis Investigative Site**

Recruiting

Kfar Saba,4428164,Israel

## **Italy**

### **Novartis Investigative Site**

Recruiting

Bassano Del Grappa,Vicenza,36061,Italy

### **Novartis Investigative Site**

Recruiting

Novara,28100,Italy

### **Novartis Investigative Site**

Recruiting

Avellino,AV,83100,Italy

### **Novartis Investigative Site**

Recruiting

Bari,BA,70124,Italy

### **Novartis Investigative Site**

Recruiting

Milano,MI,20100,Italy

### **Novartis Investigative Site**

Recruiting

Milano,MI,20122,Italy

## **Japan**

### **Novartis Investigative Site**

Recruiting

Yamagata,990 9585,Japan

### **Novartis Investigative Site**

Recruiting

Kobe,Hyogo,650-0047,Japan

**Novartis Investigative Site**

Recruiting

Isehara,Kanagawa,259-1193,Japan

**Novartis Investigative Site**

Recruiting

Narita,Chiba,286-8523,Japan

**Novartis Investigative Site**

Recruiting

Suita,Osaka,565 0871,Japan

**Novartis Investigative Site**

Recruiting

Matsuyama-city,Ehime,790-0024,Japan

**Novartis Investigative Site**

Recruiting

Itabashi-ku,Tokyo,173-8610,Japan

**Novartis Investigative Site**

Recruiting

Fukuoka city,Fukuoka,812-8582,Japan

**Novartis Investigative Site**

Recruiting

Shinjuku Ku,Tokyo,160-0023,Japan

**Novartis Investigative Site**

Recruiting

Gifu-city,Gifu,501-1194,Japan

**Novartis Investigative Site**

Recruiting

Aomori,030 8553,Japan



## **Malaysia**

### **Novartis Investigative Site**

Recruiting

Kuala Lumpur,56000,Malaysia

### **Novartis Investigative Site**

Recruiting

Penang,10050,Malaysia

### **Novartis Investigative Site**

Recruiting

Selangor,68000,Malaysia

## **Romania**

### **Novartis Investigative Site**

Recruiting

Bucuresti,013975,Romania

## **Singapore**

### **Novartis Investigative Site**

Recruiting

Singapore,S308433,Singapore

### **Novartis Investigative Site**

Recruiting

Singapore,119074,Singapore

## **Spain**

### **Novartis Investigative Site**

Recruiting

Barcelona,Catalunya,08035,Spain

### **Novartis Investigative Site**

Recruiting

Murcia,30008,Spain

## **United Kingdom**

### **Novartis Investigative Site**

Recruiting

Leeds,LS1 3EX,United Kingdom

### **Novartis Investigative Site**

Recruiting

London,E1 1BB,United Kingdom

### **Novartis Investigative Site**

Recruiting

London,W12 0HS,United Kingdom

## **United States**

### **Inspira Medical Cent Mullica Hill**

Recruiting

Mullica Hill,New Jersey,08062,United States

Jennifer Hart

Phone: [856-641-7526](tel:856-641-7526)

Email: [KartJ@ihn.org](mailto:KartJ@ihn.org)

Erev Tubb

### **Michigan Center of Medical Research**

Recruiting

Farmington Hills,Michigan,48334,United States

Faisal Musa

### **Montefiore Medical Center**

Recruiting

Bronx,New York,10461,United States

Irina Murakhovskaya

Noelle Townsend

Phone: 718-920-2680

Email: noelle.townsend@einsteinmed.edu

### **University of Colorado Anschutz**

Recruiting

Aurora, Colorado, 80045, United States

Phone: 303-724-1695

George Gemlyn

### **Gabrail Cancer Center**

Recruiting

Canton, Ohio, 44718, United States

Phone: 330-492-3345

Nashat Y Gabrail

### **University of Minnesota Med Center**

Recruiting

Minneapolis, Minnesota, 55455, United States

Diondra Howard

Email: howar709@umn.edu

Marshall Mazepa

### **STAT Research Inc**

Recruiting

Dayton, Ohio, 45402, United States

Charles Bane

### **Napa Research**

Recruiting

Margate, Florida, 33063, United States

Emilio Araujo-Mino

Maria Marin

Email: [Maria@napa-trials.com](mailto:Maria@napa-trials.com)

**Texas Oncology-Baylor Scott and White**

Recruiting

Dallas,Texas,75231,United States

Phone: [+1 214 987 6915](tel:+12149876915)

Moshe Yair Levy

**Summit Health**

Recruiting

Florham Park,New Jersey,07932,United States

Phone: [973-437-2597](tel:9734372597)

David Gallinson

**Brody School of Medicine**

Recruiting

Greenville,North Carolina,27834,United States

Phone: [252-744-3587](tel:2527443587)

Darla Liles

**NorthShore University Health System**

Recruiting

Evanston,Illinois,60201,United States

Phone: [847-570-2109](tel:8475702109)

Amy Wang

**Fred Hutchinson Cancer Center**

Recruiting

Seattle,Washington,98109,United States

Phone: [206-288-6938](tel:2062886938)

Sandhya Panch

**Baylor College Of Medicine**

Recruiting

Houston,Texas,77030,United States

Senthil Sukumar

### **Parkview Research Center**

Recruiting

Fort Wayne,Indiana,46845,United States

Jeffrey Letzer

## **Worldwide Contacts**

If the location of your choosing does not feature any contact detail, please reach out using the information below.

### **Novartis Pharmaceuticals**

Phone: +41613241111

Email:

### **Novartis Pharmaceuticals**

Phone: 1-888-669-6682

Email: [novartis.email@novartis.com](mailto:novartis.email@novartis.com)

---

**Source URL:** <https://prod1.novartis.com/clinicaltrials/study/nct05648968>

### **List of links present in page**

1. <https://clinicaltrials.gov/ct2/show/NCT05648968>
2. [#trial-eligibility](#)
3. tel:856-641-7526
4. <mailto:KartJ@ihn.org>
5. tel:718-920-2680
6. <mailto:noelle.townsend@einsteinmed.edu>
7. tel:303-724-1695
8. tel:330-492-3345
9. <mailto:howar709@umn.edu>
10. <mailto:Maria@napa-trials.com>
11. tel:+1 214 987 6915
12. tel:973-437-2597
13. tel:252-744-3587
14. tel:847-570-2109
15. tel:206-288-6938
16. tel:+41613241111
17. [mailto:](#)
18. tel:1-888-669-6682
19. <mailto:novartis.email@novartis.com>